References
- Shepherd F.A., Evans W.K., MacCormack R., et al. Cyclophosphamide, doxorubicin and vincristine in etoposide and cisplatin-resistant small cell lung cancer. Cancer Treat. Rep. 1987; 71: 941–944
- Sculier J.P., Klastersky J., Libert P., et al. A phase II study evaluating CAV; (cyclophosphamide, adriamycin, vincristine) potentiated or not by amphotericin B entrapped into sonicated liposomes, as salvage therapy for small cell lung cancer. Lung Cancer 1990; 6: 110–118
- Kubota K., Nishiwaki Y., Kokinuma R., et al. Dose-intensive weekly chemotherapy for treatment of relapsed small cell lung cancer. J. Clin. Oncol. 1997; 15: 292–296
- Van Pawel J., Schiller J.H., Shepherd F.A., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small cell lung cancer. J. Clin. Oncol. 1999; 17: 658–667
- Ettinger D.S., Finkelstein D.M., Sarma R.P., et al. Phase II study of paclitaxel in patients with extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 1995; 13: 1430–1435
- Masuda N., Fukuoka M., Kusunoki Y., et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer. J. Clin. Oncol. 1992; 10: 1225–1229
- Furuse K., Kubota K., Kawahara M., et al. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Oncology 1996; 53: 169–172
- Cormier Y., Eisenhauer E., Muldal A., et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer: a study of The National Cancer Institute of Canada Clinical Trials Group. Ann. Oncol. 1994; 5: 283–285
- Herbst R.S., Khuri F.R., Jung M., et al. Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 1999; 18: 462a, (Abstr)
- Hirsch V., Ayoub J., Cormier Y., Kerby W., Iglesias J. Phase II multicenter trial with gemcitabine and vinorelbine in patients with advanced (stage IIIB and IV) non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 1999; 18: 508a, (Abstr)
- Hainsworth J.D., Burris H.A., Litchy S., et al. Gemcitabine and vinorelbine in the second-line treatment of non-small cell lung cancer: a Minnie Pearl Cancer Research Network phase II trial. Cancer 2000; 88: 1353–1358
- Lilenbaum R., Cano R., Schwartz M., et al. Gemcitabine and vinorelbine in advanced non-small cell lung carcinoma: a phase II study. Cancer 2000; 88: 557–562
- Bajetta E., Stani S.C., DeCandis D., et al. Gemcitabine plus vinorelbine as first-line chemotherapy in advanced non-small cell lung carcinoma: a phase II trial. Cancer 2000; 89: 763–768
- Lorusso V., Carpagnano F., Frasci G., et al. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small cell lung cancer. J. Clin. Oncol. 2000; 18: 405–411
- Frasci G., Lorusso V., Panza N., et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J. Clin. Oncol. 2000; 18: 2529–2536
- Gridelli C., Frontini L., Perrone F., et al. Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Br. J. Cancer 2000; 83: 707–714
- Kaplan Z.L., Meier P. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457–481